ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,200.87
0.25%
Dow Jones
39,227.61
0.44%
US Dollar vs MXN
16.8669
-0.31%
Brent Oil
83.28
-0.34%
Bitcoin
62,021.37
1.36%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Antares Pharma Inc (ATRS)

  7. Antares Pharma Inc (ATRS) Noticias

ATRS

Antares Pharma (ATRS)

Antares Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATRS
FechaHoraFuenteTítuloSímboloCompañía
26/05/202216:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRSAntares Pharma Inc
24/05/202215:50Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ATRSAntares Pharma Inc
24/05/202215:32Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ATRSAntares Pharma Inc
24/05/202215:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
24/05/202208:08Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ATRSAntares Pharma Inc
24/05/202205:11Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ATRSAntares Pharma Inc
13/05/202215:46Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ATRSAntares Pharma Inc
12/05/202207:00PR Newswire (US)Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares PharmaNASDAQ:ATRSAntares Pharma Inc
10/05/202216:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATRSAntares Pharma Inc
06/05/202211:10Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ATRSAntares Pharma Inc
02/05/202215:50Business WireANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRSNASDAQ:ATRSAntares Pharma Inc
02/05/202205:03Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ATRSAntares Pharma Inc
29/04/202216:56Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ATRSAntares Pharma Inc
26/04/202206:17Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:ATRSAntares Pharma Inc
26/04/202206:02Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ATRSAntares Pharma Inc
14/04/202205:10Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ATRSAntares Pharma Inc
13/04/202205:00PR Newswire (US)Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery LeaderNASDAQ:ATRSAntares Pharma Inc
29/03/202206:00GlobeNewswire Inc.Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyNASDAQ:ATRSAntares Pharma Inc
07/03/202205:16TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Aclaris Therapeutics (ACRS), Antares Pharma (ATRS)NASDAQ:ATRSAntares Pharma Inc
03/03/202206:00GlobeNewswire Inc.Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsNASDAQ:ATRSAntares Pharma Inc
28/02/202207:30GlobeNewswire Inc.Antares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceNASDAQ:ATRSAntares Pharma Inc
17/02/202207:30GlobeNewswire Inc.Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating ResultsNASDAQ:ATRSAntares Pharma Inc
03/02/202207:00GlobeNewswire Inc.Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®NASDAQ:ATRSAntares Pharma Inc
01/02/202216:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRSAntares Pharma Inc
18/01/202206:30GlobeNewswire Inc.Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
12/01/202208:06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ATRSAntares Pharma Inc
12/01/202207:30GlobeNewswire Inc.Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesNASDAQ:ATRSAntares Pharma Inc
11/01/202206:30GlobeNewswire Inc.Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
17/12/202106:53GlobeNewswire Inc.MedMira strengthen its Board with New AppointmentNASDAQ:ATRSAntares Pharma Inc
15/12/202116:58GlobeNewswire Inc.Antares Pharma Announces Divestiture of Otrexup®NASDAQ:ATRSAntares Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ATRS

Su Consulta Reciente

CCOM
SILVER
SILVER
CCOM
OILBRENT
Brent Oil
NASDAQ
AAPL
Apple
PM
XAUUSD
Gold vs US Dollar
NYSE
BAC
Bank of America
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
SPI
SP500
S&P 500
CCOM
US500
US 500
FX
EURMXN
Euro vs MXN
NYSE
XOM
Exxon Mobil
NYSE
MRK
Merck
USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados